Lowest Price Guaranteed
Pages
275
Last Updated
June 2026
View Count
16407
The global targeted drug delivery device market size is projected to grow from $427 Million in 2026 to $2,153 Million by 2035, representing a CAGR of 19.7% during the forecast period.
 |
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis, clinical trial analysis, likely drug candidates and market impact analysis, along with the market forecast and opportunity analysis. The growth of the market is expected to be driven by technological advancements, increasing prevalence of chronic diseases, and a growing emphasis on personalized medicine. As research continues to evolve and new products get developed, this domain is likely to see robust market growth over the next decade.
Over the years, advancements in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene therapies under development, most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed that have led to a decrease in lung cancer and melanoma-related mortality.
 |
 |
 |
Despite their benefits, biologics present a number of challenges, such as drug delivery-related complexities and immunogenicity concerns, which have been shown to result in systemic toxicity following therapy administration. To avoid such systemic toxic effects, a limited volume of drug is often administered, which results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, biologics typically remains at the target site for a limited time, thereby decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some treatment options, such as cell therapies, require periodic administration of additional therapy materials or complementary products, thereby adding to the already complex invasive dosing procedures.
In order to address some of the abovementioned challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapy, cell / stem cell therapy, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include (in alphabetic order) Extroducer microcatheter, Helixbiotherapeutic delivery system, ImmunoPulse IL-12 and SmartFlow neuro ventricular cannula. Some of these drug delivery devices have demonstrated an improved therapeutic safety index and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to increase in the foreseen future. This is expected to create lucrative opportunities for stakeholders in this domain.
 |
 |
 |
The research report presents an in-depth analysis of targeted drug delivery devices and developers, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Forecast Period | Till 2035 | |
| Market Size in 2026 | $427 Million | |
| Market Size in 2035 | $2,153 Million | |
| Growth Rate | CAGR of 19.7% | |
| Type of Device |
|
|
| Type of Organ |
|
|
| Type of Therapy Delivered |
|
|
| Route of Administrtaion |
|
|
| Therapeutic Area |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
One of the key objectives of this market report was to estimate the current market size, future opportunity and the targeted drug delivery devices market growth potential over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution, till 2035.
The market report also features the likely distribution of the current and forecasted opportunity for targeted drug delivery device market across various segments, such as type of device (cannulas, catheters and others), type of organ (brain, breast, eyes and heart), type of therapy delivered (cell therapies, gene therapies and immunotherapies), route of administration (intratumoral, transendocardial and others), therapeutic area (cardiovascular disorders, oncological disorders, ophthalmic disorders and neurological disorders) and key geographical regions (North America, Europe and Asia-Pacific), and leading players and sales forecast.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three targeted drug delivery device market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution. The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
The global targeted drug delivery device market is categorized into different types of devices, namely cannulas, catheters and others. Currently, the revenue generated from drugs administered through cannula holds majority of share (90%) in the current market. This can be attributed to the fact that cannula can be used for both short-term and long-term applications, whereas cannulas are primarily designed for short-term use. The ability of catheters to facilitate continuous medication delivery offers significant benefits for patients suffering from chronic disorders, enabling consistent treatment over extended periods. Further, it is worth highlighting that drugs administered through catheters are likely to grow at a relatively higher CAGR during the forecast period.
This segment highlights the distribution of the market value across different types of organs, such as brain, breast, eyes and heart. The targeted drug delivery devices focused on delivering biologics directly to the breast is anticipated to capture the largest share in the current market. This can be attributed to rising prevalence of oncological disorders across the globe. Further, the market for targeted drug delivery devices delivering biologics to brain is expected to grow at the highest CAGR of 18.0%, during the forecast period.
The market is segmented across different types of therapies, namely cell therapy, gene therapy and immunotherapy. The immunotherapy market segment is likely to capture the highest (83%) targeted drug delivery device market share. This can be attributed to the fact that these therapies have shown remarkable success in targeting specific damaged cells. This specificity minimizes damage to healthy tissues, leading to improved patient outcomes and reduced side effects compared to traditional therapies. Additionally, it is worth noting that gene therapy market segment is estimated to grow at a higher annualized rate (CAGR) of 30.4%, till 2035.
This segment highlights the distribution of the market across different routes of administration, such as intratumoral, transendocardial and others. The intratumoral segment is likely to capture the highest share. This can be attributed to the fact that intratumoral route of administration minimizes the risk of side effects associated with systemic circulation. Additionally, intratumoral administration has proven to restrict the exposure of highly toxic drugs to normal tissues.
This segment highlights the distribution of targeted drug delivery device market size across various therapeutic area, including cardiovascular disorders, neurological disorders, oncological disorders and ophthalmic disorders. Currently, revenues generated by targeted drug delivery devices designed for oncological disorders occupies the highest share (83%). This can be attributed to the rising prevalence of cancer and growing research and development efforts in this field. However, the market for targeted drug delivery device targeting cardiovascular disorders is estimated to grow at a higher annualized rate (CAGR) of 23.5%, till 2035.
This segment highlights the distribution of the targeted drug delivery device market size across various geographies, namely North America, Europe and Asia-Pacific. According to our projections, currently, North America is likely to capture a majority (76%) share in the overall market. This can be attributed to the rising prevalence of chronic diseases, well developed healthcare infrastructure, and robust regulatory frameworks within this region. Further, the targeted drug delivery devices market in Europe is expected to grow at the highest CAGR of 21.3%, during the forecast period.
The "Targeted Drug Delivery Device Market: Industry Trends and Global Forecasts, till 2035" report features an extensive study of the current market landscape, market size and future opportunities for targeted drug delivery devices providers within the industry, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in targeted drug delivery device domain. Key takeaways of the market report are briefly discussed below.
Presently, close to 40 device providers are focused on offering devices for the delivery of biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins. Notably, the current market landscape features a presence of very large, large, mid-sized, small and very small companies. It is worth mentioning that the majority (51%) of the developers are headquartered in North America. This can be attributed to the robust R&D activities, supported by substantial investments from both public and private sectors. Further, the regulatory scenario in North America is generally supportive of new healthcare technologies, which helps expedite the approval processes for novel drug delivery devices.
In recent years, several pharmaceuticals / biopharmaceutical companies have invested extensively in order to evaluate the therapeutic viability and future potential of innovative pharmacological interventions. As more stem cell and gene therapies are getting approved by the regulatory authorities across the globe, the number of clinical trials across different regions is anticipated to increase as well. This can be attributed to the fact that these devices are in combination with the therapies holds great promise for enhancing treatment outcomes by maximizing efficacy, improving pharmacokinetics, addressing drug resistance, and paving the way for more personalized medicine approaches.
The global market for targeted drug delivery device is estimated to be worth USD 427 million in the 2026; the growth in this market is primarily driven by the increasing prevalence of chronic diseases, ongoing technological advancements and need for personalized medicine. As a result of these factors, the need for targeted drug delivery solutions has surged and the market is projected to grow at a CAGR of 19.7% during the forecast period.
Currently, close to 80% of the market demand for targeted drug delivery devices is captured by North America, owing to the growing preference for personalized medicines, especially for patients suffering from oncological disorders. Additionally, increasing health concerns related to chronic diseases are further driving market growth in this region. It is worth highlighting that the market size in Europe is expected to grow at higher CAGR of 21.3%, during the forecast period.
Currently, close to 80% of the market demand for targeted drug delivery devices is captured by North America, owing to the growing preference for personalized medicines, especially for patients suffering from oncological disorders. Additionally, increasing health concerns related to chronic diseases are further driving market growth in this region. It is worth highlighting that the market size in Europe is expected to grow at higher CAGR of 21.3%, during the forecast period.
Examples of top players in targeted drug delivery device industry (have been profiled in this market report; in alphabetical order) include Alcyone Therapeutics, Algorae Pharmaceuticals, BioCardia, ClearPoint Neuro, Gloriana Therapeutics, Mercator MedSystems, Neurotech Pharmaceuticals, Novartis, OncoSec, PharmaCyte Biotech, PulseSight Therapeutics, Renishaw, Silexion Therapeutics and SmartCella. This market report includes an easily searchable excel database of targeted drug delivery device developers present worldwide.
The market report presents an in-depth analysis, highlighting the capabilities of various targeted drug delivery device providers in this market, across different segments. Amongst other elements, the market report includes:
Driven by numerous developmental breakthroughs and result of studies demonstrating the vast potential of targeted drug delivery devices in addressing the health-related concerns associated with prevalence of chronic diseases, have garnered considerable attention of various market players engaged in the targeted drug delivery devices industry.
Several developments have taken place in the field of needles over the past few years. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall targeted drug delivery device market trends that have been outlined in our analysis.